Innocan Pharma (INNPF) is a leading pioneer, since the outbreak of the global COVID-19 pandemic, market analysts have observed rising global demand for exosome-derived technologies and solutions. In 2020 the global exosomes market was valued at some $174.04 million, and its projected CAGR is 27.89% for the period of 2023-2026. In tandem, the exosome industry is witnessing rising numbers of clinicals trials investigating exosomes’ applications to biotech, therapeutics, and diagnostics.
But let’s take a step backwards. For starters, what exactly are exosomes? Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 150 nanometers. Exosomes are secreted by a wide range of cells, since virtually all living cells utilize exosome-mediated communication. One highly-active area of ongoing exosome R&D is in the field of exosome-loading platforms for more effective delivery of drugs and therapeutic substances to the body.
Numerous approaches are being researched for creating drug-loaded exosomes and they can exert powerful therapeutic effects. For example, exosomes have promising potential to be a vehicle for drug delivery as they have natural material transportation properties, the capability to support intrinsic long-term circulation, and high biocompatibility. Given these intrinsic characteristics, exosomes have the capability to serve as a therapeutic platform for many diseases, including COVID-19.
Innocan Pharma (CSE: INNO)(OTCQB: INNPF)(FSE: IP4) is now one of a few public companies currently blazing ahead with research in the exosome industry. In collaboration with partners at Tel Aviv University’s Sagol School of Neuroscience, Innocan is working to develop a revolutionary cell CBD-loaded exosome delivery platform to target acute bodily inflammation.
Innocan’s CLX Therapy holds the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product is planned to act as a “guided missile” to the infected lungs, combining the cell healing properties of exosomes and the anti-inflammatory properties of CBD. Innocan has successfully manufactured trillions of exosomes in a short period of time by using a 3-dimensional bioreactor, which is an encouraging sign of their methods’ scalability in light of surging global demand.
Innocan is currently moving forward with the R&D for its CLX technology, and recently declared its intention to enter a comprehensive Research and License Agreement with Ramot, the official technology transfer company of Tel Aviv University.
To date I’m unaware of any potential competitors working on exosome-based solutions for the delivery of CBD to affected areas of the body; in this respect, they rank as a true pharma disruptor. Innocan stock is currently trading at around $0.50, meaning there is a low barrier of entry to any investors willing to wager on growing global demand for exosome-based technologies and therapies. Take it or leave it, this ain’t financial advice, but exosome may very well be the next “hot thing” in biotech.
This article was written by u/EagleEyeStx.
